Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088177 · ClinicalTrials.gov registry record · Phase 1
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02088177 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants.
The verdict
NCT02088177, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an 8 week, outpatient research study testing the use of long-acting naltrexone (Vivitrol) as a treatment for marijuana dependence. Vivitrol is a medication that is effective in treating dependence on opiates and opioids, and in treating dependence on alcohol. It is FDA approved for these disorders. It is a long-acting medication that contains enough medicine in each injection to last for one month. One way it works is by blocking the effects of opiates, including opiates released by the body in response to drugs and alcohol. In this study, we are interested in testing the effects of Vivitrol in people with marijuana dependence. Individuals participating in this study will receive two Vivitrol injections, each given four weeks apart, (week 1 and week 5). The injection is given in the muscle of the buttock on one side. Participants will attend clinic visits two times a week during this 8-week study for medical management for drug use and for monitoring of physical and psychological health.
Interventions
- DRUG Long-acting injectable naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02088177
The ClinicalTrials.gov registry entry for NCT02088177 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Long-acting injectable naltrexone is the first listed.
NCT02088177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02088177 about?
NCT02088177 is a clinical study titled "Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence". This is an 8 week, outpatient research study testing the use of long-acting naltrexone (Vivitrol) as a treatment for marijuana dependence. Vivitrol is a medication that is effective in treating dependence on opiates and opioids, and in treating dependence on alcohol. It is FDA approved for these dis...
What is the current status of trial NCT02088177?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-10. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02088177?
The interventions under investigation include: Long-acting injectable naltrexone (DRUG).
Who is sponsoring clinical trial NCT02088177?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.